Trial Profile
Priming the Tumour MicroEnvironment for Effective Treatment With Immunotherapy in Locally Advanced Rectal Cancer A Phase II Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms PRIME-RT
- 18 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2023 Trial design presented at the 2023 Gastrointestinal Cancers Symposium